Floatz logo

DARATUMUMAB

MRD

The First Affiliated Hospital of Soochow Universitymonoclonal_antibodyPhase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the MRD cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
The First Affiliated Hospital of Soochow University
Phase 4BB
cc-5013
The First Affiliated Hospital of Soochow University
Phase 4BB
DEXAMETHASONE
The First Affiliated Hospital of Soochow University
Phase 4BB
Carfilzomib
The First Affiliated Hospital of Soochow University
Phase 4BB
FILGRASTIM
The First Affiliated Hospital of Soochow University
Phase 4BB

View all 15 →

Same molecule, other indications

DARATUMUMAB is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
smoldering plasma cell myelomaDormant
BB
Indicative ·
65 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →